We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Epoprostenol now the focus of numerous clinical trials

William A. Check
JAMA. 1981;245(24):2481-2483. doi:10.1001/jama.1981.03310490003001.
Text Size: A A A
Published online


Evidence is fast accumulating on the therapeutic value of one of the newest members of the prostaglandin family, epoprostenol, which was discovered in 1976.

In the United States recently to deliver a lecture, John Vane, DSc, group research director at the Burroughs Wellcome Foundation, Beckenham, England, described for JAMA MEDICAL NEWS some of the clinical trials in which the compound has proved its value as an inhibitor of platelet aggregation. Vane received the Lasker Award in 1977 for his prominent role in the discovery of epoprostenol, also known as PGI2 and more commonly as prostacyclin.

Other information on epoprostenol comes from a recent conference on prostaglandins in cerebrovascular and thrombotic disorders held in Chicago under the auspices of Rush Medical College and Northwestern University Medical School.

Epoprostenol was actually discovered by Vane and Salvador Moncada during their search for thromboxane, the prostaglandin that promotes aggregation of platelets, in the endothelium


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.